Bobby_J_Bomb Posted - 13 hours ago

$AADI Updates coming through end of year. Can hit with known interim updates or synergy/collaborstion data surprises!! $4+/share cash and funded through 2025 and all major phase 2 and registrational studies!! Only 16 mm float, so if this goes on expansion approval in billion dollar markets or ahows synergy with major existing drugs for high prevalance cancers, FOMO will be huge!!

Endif Posted - 1 day ago

$AADI got my avg down to 7.93 from 10. Painful but optimistic. Will keep adding as I get premium elsewhere.

Bobby_J_Bomb Posted - 1 day ago

$AADI If this gets approved for expansion to ALL Tsc1 and/or Tsc2 mitations in mTor, which I believe at least Tsc1 will (smart that they separared) these are the breadcrumbs that the market missed that they should've paid more attentuon to. First, if the SD continues in the other 6 of 9 through at least 6 months, clinical benefit becomes 14/19=72%. Second, this is a registrational trial and could go for immediate approval upon completion later this year. Third, this is a tissue agnostic trial, meaning ALL tissue types with TSC1 mutation would be approved. The fact that the ORR were in four DIFFERENT carcinoma types is HUGE!! It makes the case that MOA is in mTor pathway with this mutation and not tissue specific. Finally, the approval is for an mTor sarcoma, PEComa, so it shows both sarcomas and carcinomas respond and based on 3 year data, results get better with increased ORR over time.

Lolol11 Posted - 2 days ago

$AADI $4 by the end of the month?

SlapThatAsssk Posted - 2 days ago

$AADI - accumulating here

Jarvis7424 Posted - 2 days ago

$AADI my goodness this is SILLY AS FUCK. Wake up

Bobby_J_Bomb Posted - 3 days ago

$AADI 0.40 price/cash with $25mm in annual sales on commercial approval, and registrational expansion trial data due by early 2025 thst could open up 2 x multi-billion dollar addressable market channels. Also, 2 other phase 2 triap interim data due by end of year, as well as excellent preclinical synergy data that may play well into the Mirati collab for NSCLC. This market is all hyped up for one thing, AI, and the restrictions, foreign knockoff competition, damage to employment market (aka, the consumer), plateus and tech barriers arent even being factored in.

bloodee Posted - 3 days ago

$AADI slow bleeding, then Neil's kick in the nuts to investors/gamblers in a couple of weeks! Looking forward to it!

Bobby_J_Bomb Posted - 3 days ago

$AADI no volume and no market oversight means whoever is fucking with this can do whatever they want. Retail tradera are crushed by algos and MM and HF have cookes the markwt on Biden money print and AI optimized hype without factoring risks and headwinds. Looks like double bottom coming before next move up. Ill add there.

lossaversion Posted - 3 days ago

$AADI I keep loading for the big payday in Dec '24

Jarvis7424 Posted - 3 days ago

$AADI no reason for this

lossaversion Posted - 4 days ago

$AADI 40K shares at 1.9872... one day this will be 30 bucks a share is my bet

Bobby_J_Bomb Posted - 6 days ago

$AADI opened up another $50k in case this tanks with markets. $FUSN is best example of a comparqble that had similar price action before data brought it back and culminated in a $2.4 bn buyout. AADI probably best r/r in bio right now with tsc1 and tsc2 data read in q3, registrational study for.multi-billion market complete by end of 2024 and rwsdout in early 2025....all while trading at 0.40 price/cash and runway through registrational final and other phase 2 studies in endometrial and neuroendocrine mutations. Best part is that the commercial application for tsc1 and tsc2 mutations in PEComa is based on the same MOA and early results are trending the same. Also, 3 year follow up data shows results are even better over a longer timeframe and confirm efficacy absolutely!!

PaytiencePaysGreen Posted - 1 week ago

$AADI low volume again...no matter

Jarvis7424 Posted - 1 week ago

$AADI another day closer to Q3

Bobby_J_Bomb Posted - 1 week ago

$AADI if this hits, shares will be hard to come by.

Bobby_J_Bomb Posted - 1 week ago

$AADI high inside ownership and founder/bod director on auto sales for salary structure = likely very receptive to buyout offer that could come at any time. One of their board members has been involved with a few similar buyouts, and FUSN, which isnt even commercial stage with evwn better 3 year data of FYARRO, jist sold for $2.4 bn.

G101SPM Posted - 1 week ago

$AADI $1.93 ask BUY/ADD TO POSITION carries SPM 87.01 tag with EXIT at $4.00. DAC (2) $2.045.

5by5 Posted - 1 week ago

$AADI ?

Bobby_J_Bomb Posted - 1 week ago

$AADI same short group that had been doing this across low volume penny stocks for weeks. They crash it on low volume by buying lots and selling to themselves and trying to accumulate by triggering sells. Another BS mechanism of the market that is illegal, but goes unchecked. Patient...as good nimbers in ysc1 or 2 will break this past $10 quickly. If not, they have other phase 2 data coming that could be even bigger.

TideCharts13 Posted - 1 week ago

$AADI what caused the gap down in December?

Jarvis7424 Posted - 1 week ago

$AADI this is silly lol

lossaversion Posted - 1 week ago

$AADI good day to top up a bit for me

Bobby_J_Bomb Posted - 1 week ago

$AADI momentum alone could get this to $4 before Q3 data. If data is good to great, this will be a blockbuster as tsc1 and tsc2 (each billion dollar markets) mutations market would be almost entirely forecast as AADI's if they receive approval after study completion in late 2024 as this is a registrational study. Furthermore, the probability of FYARRO working alone or synergistically gor major improvements in other mutation cancers will increase substantially. In theory, could go back to fill $60, as that would only be $1.5 bn MC with multi-billion dollar potential for at least 2 decades while patents hold up.

PaytiencePaysGreen Posted - 1 week ago

$AADI super low volume day. MM and Algo stealing your shares

Nik_CA Posted - 1 week ago

$AADI What is the total authorized shares for this company? O/S is around 25 million.

G101SPM Posted - 1 week ago

$AADI $$2.16

G101SPM Posted - 1 week ago

$AADI $2.16 ask.... BUY/NEW HOLDING carries a SPM 87.02 tag with short term EXIT at $4.00. note: High SPM tag with 210 bits increase in the last two hours.

G101SPM Posted - 1 week ago

@Midvale $AADI $2.13... Requested: Today announced to submit data during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, taking place April 5-10, 2024. Posters Titled: "Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines" Presenting Author:Shihe Hou, PhD Session Title: Reversal of Drug Resistance Poster Number: Poster Section 25; Poster 6 Date/Time: Wednesday, April 10, 2024, 9:00 AM – 12:30 PM "Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors" Presenting Author:Shihe Hou, PhD Session Title: Targeting Kinase and ERK Pathways Poster Number: Poster Section 46; Poster 3 Date/Time: Tuesday, April 9, 1:30 – 5:00 PM.

Bobby_J_Bomb Posted - 1 week ago

$AADI still dont know how FUSN geta a $2.4 bn buyout with no revenue in phase 2 while this sits at $50 mn. Going to stick with my original gut here, despite Neil selling monthly on auto sells....I will assume it is a hedge.